Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Stromal vascular fraction (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Translational Biosciences
- 16 Sep 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 21 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 01 Aug 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.